- Patents for pharmaceuticals intact: The 2013 transition period extension agreement does not apply to the current expectation on LDCs to provide for patent protection for pharmaceutical products from 1st January 2016 ('The 2002 transition period agreement'). (Afro Leo notes that LDCs have the right, like they have successfully done this month, to seek for a further extension of the 2002 agreement)
- Non roll-back provision: Unlike the stronger wording in the 2005 transition period extension agreement, LDCs have now only expressed a willingness not to reduce or do away with their current IPRs protection if they have already voluntarily implemented TRIPS. (Afro Leo thinks that most have voluntarily done so or probably coerced to do so by trading partners).
- May continue to implement and/or apply TRIPS: LDCs may continue with their progress in TRIPS implementation and fully utilise its flexibilities such as introducing compulsory licensing to get around patent rights and this does not count as rollback. Developed countries are also expected to offer incentives to support LDCs' technological base.
For a history on TRIPS and LDCs, see here
For global academics's expert support for unconditional extension of TRIPS, see here
For ICTSD's commentary on this, see here and for IP-Watch, see here